| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e8d2afa63dbd8bbb90545722d3f54c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_efb8cb4e6ee6d1a16d7b6a7ec55377b3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2012-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89a5d6271054f8123f0abb24acd42503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b004c557b7c1540baad0439ff4b5f4d |
| publicationDate |
2014-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20140047138-A |
| titleOfInvention |
A method for determining the efficacy of a fusion gene of a VIIF5 gene and a RET gene and cancer therapy targeting the fusion gene |
| abstract |
In cancer, a gene for identifying a gene that can be used as an index for predicting the effectiveness of treatment with a drug and targeting the gene to provide a novel method for predicting the effectiveness of treatment with a drug, Whole transfectome sequencing of cancer was performed. As a result, in-frame fusion transcription products were identified between the KIF5B gene and the RET gene. This KIF5B-RET gene fusion was detected in 6/319 (2%) of Japanese lung adenocarcinoma and 1/80 (1%) of American lung adenocarcinoma. And since none of these seven examples showed known activation mutations such as EGFR, KRAS, and ALK cancer genes, the gene fusion was found to be responsible mutations (driver mutations) in cancerization. Since the gene fusion is thought to cause constant activation of the RET tyrosine kinase protein, it was found that treatment with an inhibitor against the RET tyrosine kinase is effective for patients in which the gene fusion is detected. |
| priorityDate |
2011-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |